MA54877A - Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur - Google Patents
Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeurInfo
- Publication number
- MA54877A MA54877A MA054877A MA54877A MA54877A MA 54877 A MA54877 A MA 54877A MA 054877 A MA054877 A MA 054877A MA 54877 A MA54877 A MA 54877A MA 54877 A MA54877 A MA 54877A
- Authority
- MA
- Morocco
- Prior art keywords
- psychological
- behavioral
- cognitive
- compositions
- treatment
- Prior art date
Links
- 208000019022 Mood disease Diseases 0.000 title 1
- 230000003542 behavioural effect Effects 0.000 title 1
- 230000001149 cognitive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000952 serotonin receptor agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962798998P | 2019-01-30 | 2019-01-30 | |
US201962799010P | 2019-01-30 | 2019-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54877A true MA54877A (fr) | 2021-12-08 |
Family
ID=71841404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054877A MA54877A (fr) | 2019-01-30 | 2020-01-29 | Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur |
Country Status (12)
Country | Link |
---|---|
US (2) | US20220096504A1 (fr) |
EP (1) | EP3917537A4 (fr) |
JP (1) | JP2022523700A (fr) |
KR (1) | KR20210134313A (fr) |
CN (1) | CN114040767A (fr) |
AU (1) | AU2020215150A1 (fr) |
BR (1) | BR112021014750A2 (fr) |
CA (1) | CA3127854A1 (fr) |
IL (1) | IL285186A (fr) |
MA (1) | MA54877A (fr) |
MX (1) | MX2021009037A (fr) |
WO (1) | WO2020157569A1 (fr) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
CA3132731A1 (fr) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions et methodes d'utilisation comprenant des substances ayant des actions de plasticite neurale administrees a des doses et formulations non psychedeliques/psychotomimetiques |
KR20220009955A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료 |
WO2021067626A2 (fr) | 2019-10-01 | 2021-04-08 | Intima Bioscience, Inc. | Génie génétique de champignons pour moduler l'expression de tryptamine |
WO2021072530A1 (fr) * | 2019-10-15 | 2021-04-22 | Tassili Life Sciences, Corp. | Formulations à libération contrôlée d'agents dérivés de psilocybes et leur procédé d'utilisation, et procédés et compositions pour traiter une lésion cérébrale traumatique légère avec un syndrome de stress post-traumatique |
WO2021108911A1 (fr) * | 2019-12-04 | 2021-06-10 | Neonmind Biosciences Inc. | Utilisation de psilocine, de psilocybine ou analogues associés pour la perte de poids, le traitement de l'obésité et de l'hyperphagie boulimique |
US20210220336A1 (en) * | 2020-01-22 | 2021-07-22 | Clexio Biosciences Ltd. | Topical detomidine formulations |
KR20220137085A (ko) | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 3-피롤리딘-인돌 유도체 |
CN115974757A (zh) | 2020-02-04 | 2023-04-18 | 明德赛特制药公司 | 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物 |
EP4135713A4 (fr) * | 2020-04-17 | 2024-04-17 | Revive Therapeutics Ltd | Utilisation de psilocybine dans le traitement d'une lésion cérébrale neurologique et de migraines |
BR112022022331A2 (pt) | 2020-05-05 | 2022-12-20 | Univ Basel | Método para melhorar efeitos terapêuticos positivos de um psicodélico, composição, e método para tratar um paciente |
WO2021226416A1 (fr) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Nouvelles compositions de matière et compositions pharmaceutiques |
EP4153564A1 (fr) | 2020-05-19 | 2023-03-29 | Cybin IRL Limited | Dérivés de tryptamine deutérés et procédés d'utilisation |
WO2021243460A1 (fr) * | 2020-06-03 | 2021-12-09 | Neonmind Biosciences Inc. | Méthode thérapeutique de perte de poids |
EP4188367A1 (fr) * | 2020-07-29 | 2023-06-07 | Diamond Therapeutics Inc. | Agonistes de récepteur 5-ht à libération prolongée pour des affections neurologiques |
US20220062310A1 (en) * | 2020-09-03 | 2022-03-03 | Yale University | Psilocybin in patients with obsessive-compulsive disorder |
WO2022072808A1 (fr) * | 2020-10-01 | 2022-04-07 | Mydecine Innovations Group Inc. | Nouvelles compositions psychédéliques, systèmes d'administration et leurs utilisations thrapeutiques |
WO2022079574A1 (fr) * | 2020-10-12 | 2022-04-21 | Goodcap Pharmaceuticals Ltd. | Compositions pour la réduction de l'inflammation dans le but d'améliorer ou d'entretenir la santé mentale ou physique |
US20230398234A1 (en) * | 2020-10-28 | 2023-12-14 | Mydecine Innovations Group Inc. | Novel fungal compoind formulations and their therapeutic methods of use |
WO2022115796A1 (fr) * | 2020-11-30 | 2022-06-02 | Wesana Health Inc. | Compositions et méthodes de traitement de pathologies neurologiques |
WO2022115798A2 (fr) * | 2020-11-30 | 2022-06-02 | Wesana Health Inc. | Compositions et méthodes de traitement de la migraine |
US20240025850A1 (en) * | 2020-12-09 | 2024-01-25 | Caamtech, Inc. | Dialkyl tryptamines and their therapeutic uses |
CA3197443A1 (fr) | 2020-12-28 | 2022-06-28 | Psilo Scientific Ltd. | Procedes d'extraction d'alcaloides psychoactifs et preparation connexe en formes transmucosales |
US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
WO2022189855A1 (fr) * | 2021-03-08 | 2022-09-15 | Diamond Therapeutics Inc. | Titrage d'agonistes du récepteur sérotoninergique |
WO2022204323A1 (fr) * | 2021-03-24 | 2022-09-29 | The Trustees Of Columbia University In The City Of New York | Analogues d'ariadne non hallucinogènes pour le traitement de troubles neurologiques et psychiatriques |
WO2022207746A1 (fr) * | 2021-03-30 | 2022-10-06 | Compass Pathfinder Limited | Compositions de psilocybine, leurs méthodes de fabrication et leurs méthodes d'utilisation |
WO2022212789A1 (fr) * | 2021-03-31 | 2022-10-06 | Mycrodose Therapeutics Inc. | Système transdermique, formulation et méthode d'administration thérapeutique d'un agent psychédélique |
WO2022221554A2 (fr) * | 2021-04-16 | 2022-10-20 | Callitas Health Inc. | Compositions et procédés pour l'administration de psilocine et de promédicaments de celle-ci |
WO2022221942A1 (fr) * | 2021-04-19 | 2022-10-27 | Betterlife Pharma Inc. | Prévention du détournement de médicaments |
JP2024516827A (ja) * | 2021-04-30 | 2024-04-17 | マインド メディシン, インコーポレイテッド | Lsd塩結晶形態 |
WO2022235514A1 (fr) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Administration de psychotropes par liposome |
CA3222412A1 (fr) * | 2021-06-07 | 2022-12-15 | University Of Mississippi | Procedes de distribution pulsee d'agents bioactifs |
US11801256B2 (en) | 2021-06-08 | 2023-10-31 | Universitätsspital Basel | Antidepressant-psilocybin co-treatment to assist psychotherapy |
GB202109023D0 (en) * | 2021-06-23 | 2021-08-04 | Ldn Pharma Ltd | Compositions comprising an agonist of 5-hydroxytryptamine (5-ht) receptor subtype 3 |
WO2022272176A1 (fr) * | 2021-06-25 | 2022-12-29 | Synaptive Therapeutics, Llc | Analogues de psilocybine pour le traitement de troubles psychologiques |
IL311211A (en) * | 2021-09-03 | 2024-05-01 | Alexander Shulgin Res Institute Inc | Asymmetric allyl tryptamines |
CA3237988A1 (fr) | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybine et o-acetylpsilocine, leurs sels et formes a l'etat solide |
TW202340147A (zh) * | 2021-11-12 | 2023-10-16 | 美商泰仁生物科學公司 | 賽洛西賓(psilocybin)及o-乙醯基脫磷酸裸蓋菇素(o-acetylpsilocin)、其鹽及其固態形式 |
WO2023137094A1 (fr) * | 2022-01-12 | 2023-07-20 | Eleusis Therapeutics Us, Inc. | Formulation de benzoate de psilocine pour perfusion intraveineuse |
WO2023183618A1 (fr) * | 2022-03-25 | 2023-09-28 | Ojai Energetics Pbc | Compositions psychédéliques et leurs procédés de formation |
WO2023212230A1 (fr) * | 2022-04-27 | 2023-11-02 | Howard Hughes Medical Institute | Récepteurs chimiogénétiques et leurs procédés de fabrication et d'utilisation |
WO2023220366A1 (fr) * | 2022-05-13 | 2023-11-16 | Reset Pharmaceuticals, Inc. | Administration d'un composé psychédélique par injection sous-cutanée |
WO2023248222A1 (fr) * | 2022-06-21 | 2023-12-28 | Technion Research & Development Foundation Limited | Agents modulateurs du récepteur 5-ht2c pour le traitement de troubles neurodégénératifs, mentaux, cognitifs et auto-immuns |
WO2024015447A1 (fr) * | 2022-07-12 | 2024-01-18 | Lobe Sciences Ltd. | Préparation de sels, d'esters et de conjugués de psilocine stables et leurs utilisations |
WO2024019908A1 (fr) * | 2022-07-19 | 2024-01-25 | Lobe Sciences Ltd. | Agent psychédélique sérotoninergique pour le traitement du mutisme sélectif |
WO2024079648A1 (fr) * | 2022-10-11 | 2024-04-18 | Sintalica S.R.L. | Système d'administration pour la libération contrôlée d'un composé psychédélique, composition pharmaceutique et utilisations associées |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
CN108619214A (zh) * | 2017-03-15 | 2018-10-09 | 王慎君 | 一种治疗肿瘤的药物 |
-
2020
- 2020-01-29 BR BR112021014750-0A patent/BR112021014750A2/pt unknown
- 2020-01-29 WO PCT/IB2020/000052 patent/WO2020157569A1/fr unknown
- 2020-01-29 CN CN202080027002.3A patent/CN114040767A/zh active Pending
- 2020-01-29 AU AU2020215150A patent/AU2020215150A1/en active Pending
- 2020-01-29 EP EP20748736.4A patent/EP3917537A4/fr active Pending
- 2020-01-29 MX MX2021009037A patent/MX2021009037A/es unknown
- 2020-01-29 CA CA3127854A patent/CA3127854A1/fr active Pending
- 2020-01-29 US US17/427,037 patent/US20220096504A1/en not_active Abandoned
- 2020-01-29 JP JP2021543489A patent/JP2022523700A/ja active Pending
- 2020-01-29 MA MA054877A patent/MA54877A/fr unknown
- 2020-01-29 KR KR1020217026762A patent/KR20210134313A/ko unknown
-
2021
- 2021-07-28 IL IL285186A patent/IL285186A/en unknown
-
2022
- 2022-11-08 US US18/053,648 patent/US20230113351A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230113351A1 (en) | 2023-04-13 |
AU2020215150A1 (en) | 2021-09-09 |
US20220096504A1 (en) | 2022-03-31 |
IL285186A (en) | 2021-09-30 |
CN114040767A (zh) | 2022-02-11 |
BR112021014750A2 (pt) | 2021-09-28 |
MX2021009037A (es) | 2021-10-13 |
WO2020157569A1 (fr) | 2020-08-06 |
KR20210134313A (ko) | 2021-11-09 |
CA3127854A1 (fr) | 2020-08-06 |
JP2022523700A (ja) | 2022-04-26 |
EP3917537A4 (fr) | 2022-09-07 |
EP3917537A1 (fr) | 2021-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54877A (fr) | Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur | |
MA28660B1 (fr) | Composes et compositions en tant que modulateurs de ppar | |
MA30339B1 (fr) | Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1 | |
MA49682A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
MA51673A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
EA202190661A1 (ru) | Агонисты фарнезоидного х-рецептора для лечения заболевания | |
MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
MA33593B1 (fr) | Composés hétérocycliques et leurs utilisations | |
BRPI0511527A (pt) | compostos e composições como moduladores de ppar | |
BR0314192A (pt) | Antagonistas de receptores de mglu para tratamento de distúrbios associados com receptores de mglu incluindo vìcio e depressão | |
MA56387A (fr) | Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf | |
EP3952840A4 (fr) | Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs | |
EP3973586A4 (fr) | Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs | |
MX2022001874A (es) | Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos. | |
BRPI0510024A (pt) | compostos e composições como modulares de ppar | |
MA30798B1 (fr) | Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1 | |
MA56047A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting | |
MA51568A (fr) | Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central | |
MA52616A (fr) | Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses | |
ATE284693T1 (de) | Verwendung von dopamin-d 3-rezeptorantagonisten zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen | |
WO2018067520A3 (fr) | Procédés et agents thérapeutiques | |
DE602005026543D1 (de) | Zusammensetzungen und verfahren zur behandlung kognitiver störungen | |
MA54792A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires |